Drug Trial Radar · NCT05046431
Comparative Study of BAT2506 With Simponi® in Participants With Active Psoriatic Arthritis
Last checked: Nov 20, 2026Latest source record: Oct 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
704
Actual
Start
May 6, 2021
Primary completion
Oct 6, 2023
Study completion Oct 6, 2023
Sponsor
- Lead sponsor
- Bio-Thera SolutionsIndustry
- Sponsor type
- Industry
- First posted
- Sep 16, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, double-blind, randomized, parallel-group study to compare the efficacy,pharmacodynamics (PD), pharmacokinetics (PK), safety, and immunogenicity of BAT2506 versus Simponi® in participants with active PsA. The study will consist of up to 4-week Screening Period, a 52-week Treatment Period, and a 8-week Safety Follow-up Period.
Conditions
- Psoriatic Arthritis
Interventions
BAT2506Drug
50mg/0.5mL
EU SimponiDrug
50mg/0.5mL
Primary outcomes
What the sponsor says the trial is designed to measure.
- ACR20Time frame: Week 8 for EMA or Week 14 for FDA and NMPA
Locations
1 site in 1 country. Site status is shown where the registry gives one.
West China Hospital Sichuan University
Chengdu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.